Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to $79597.0.

  • Pharma-Bio Serv's Change in Accured Expenses rose 24592.9% to $79597.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$853006.0, marking a year-over-year increase of 2934.77%. This contributed to the annual value of -$853006.0 for FY2025, which is 2934.77% up from last year.
  • Per Pharma-Bio Serv's latest filing, its Change in Accured Expenses stood at $79597.0 for Q4 2025, which was up 24592.9% from -$121631.0 recorded in Q3 2025.
  • Pharma-Bio Serv's Change in Accured Expenses' 5-year high stood at $360860.0 during Q3 2021, with a 5-year trough of -$764001.0 in Q2 2021.
  • In the last 5 years, Pharma-Bio Serv's Change in Accured Expenses had a median value of -$121631.0 in 2025 and averaged -$166539.8.
  • Per our database at Business Quant, Pharma-Bio Serv's Change in Accured Expenses surged by 30527.19% in 2023 and then crashed by 161845.27% in 2024.
  • Pharma-Bio Serv's Change in Accured Expenses (Quarter) stood at $189423.0 in 2021, then plummeted by 144.02% to -$83385.0 in 2022, then plummeted by 285.47% to -$321427.0 in 2023, then skyrocketed by 83.03% to -$54545.0 in 2024, then surged by 245.93% to $79597.0 in 2025.
  • Its Change in Accured Expenses was $79597.0 in Q4 2025, compared to -$121631.0 in Q3 2025 and -$597831.0 in Q2 2025.